Business
Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin Predictions are Best-in-Class and Identify when Patients have been Misdiagnosed
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, recently published a study on the development and validation of Caris' latest version of Caris GPSai™ in AACR's Cancer Research Communications Journal. Caris GPSai is a clinically validated deep learning multi-layer AI that leverages comprehensive whole exome and whole transcriptome sequencing (WES/WTS) to significantly improve diagnostic accuracy for cancers of unkn
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"Caris GPSai™ utilizes deep learning to significantly improve diagnostic accuracy for cancers of unknown primary and misclassified tumors","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"IRVING, Texas, Aug. 5, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, recently published a study on the development and validation of Caris' latest version of Caris GPSai™ in AACR's Cancer Research Communications Journal. Caris GPSai is a clinically validated deep learning multi-layer AI that leverages comprehensive whole exome and whole transcriptome sequencing (WES/WTS) to significantly improve diagnostic accuracy for cancers of unknown primary (CUP) and identify patients who have potentially misdiagnosed tumors.","length":643,"tagName":"p"},{"type":"image","alt":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","displaySize":"","headline":null,"caption":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":359,"url":"https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MqHe21QS1MqglPOGiTFaYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYzMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8","width":400,"height":359}},"href":"https://mma.prnewswire.com/media/830740/Caris_Life_Sciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This latest advancement marks a shift from traditional machine learning to a deep learning-based approach, enabling more precise prediction of tumor tissue of origin and the identification of potential misdiagnoses during routine molecular profiling, ultimately supporting more informed treatment decisions and potentially improving patient outcomes.","length":350,"tagName":"p"},{"type":"text","content":"The enhanced Caris GPSai was trained on WES/WTS data from over 200,000 Caris-profiled cases and classifies tumors into 90 categories. The tool demonstrated 95.0% accuracy in identifying tumor tissue of origin in non-CUP cases and successfully reported a tissue of origin in 84.0% of CUP and 96.3% of non-CUP cases during retrospective (N=21,549) and pr...